TAUNS Laboratories, Inc. Logo

TAUNS Laboratories, Inc.

Develops and sells in vitro diagnostics and research reagents, like antigen tests, globally.

197A | T

Overview

Corporate Details

ISIN(s):
JP3452250008
LEI:
Country:
Japan
Address:
伊豆の国市神島761番1
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TAUNS Laboratories, Inc., founded in 1987, is a company engaged in the development, manufacture, and sale of in vitro diagnostics (IVD) and research reagents. The company's mission is to enrich lives and provide peace of mind through its proprietary diagnostic technologies. Its main products include antigen test kits for infectious diseases and various analytical reagents. A key focus for the company is the development of patient-friendly products for global consumption, facilitated through its export and import operations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-25 09:49
Registration Form
確認書
Japanese 8.1 KB
2025-09-25 09:47
Annual Report
有価証券報告書-第10期(2024/07/01-2025/06/30)
Japanese 2.0 MB
2025-02-13 07:30
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-02-13 07:30
Interim Report
半期報告書-第10期(2024/07/01-2025/06/30)
Japanese 174.5 KB
2024-09-30 03:19
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2024-09-27 08:00
Registration Form
確認書
Japanese 8.1 KB
2024-09-27 08:00
Governance Information
内部統制報告書-第9期(2023/07/01-2024/06/30)
Japanese 22.1 KB
2024-09-27 08:00
Annual Report
有価証券報告書-第9期(2023/07/01-2024/06/30)
Japanese 1.9 MB
2024-06-12 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB
2024-06-04 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB
2024-05-17 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 4.7 MB

Automate Your Workflow. Get a real-time feed of all TAUNS Laboratories, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAUNS Laboratories, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAUNS Laboratories, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.